Patients with defects in the IL-12/IFNγ activation pathways are at increased risk of severe mycobacterial and Salmonella infections [5], and recombinant IFNγ is an established therapy in patients with chronic granulomatous disease [6]. This evidence concerns the gene IFNG and chronic granulomatous disease.